SCHEMBL3107014

SCHEMBL3107014

[CH2]c1cccc(C(Br)(c2cccc([CH2])c2)c2cccc(Cl)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.41
CYP19A1 P11511 2/20 0.39
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 2/20 0.33
PNMT P11086 1/20 0.32
SCN5A Q14524 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3110397 0.86 CYP19A1 (0.38) KIF11CYP19A1ALDH1A1TSHRMAPK1
SCHEMBL29048828 0.81 KIF11 (0.49) KIF11CYP19A1ALDH1A1TSHRMAPK1
SCHEMBL3099093 0.81 KCNN4 (0.33) KIF11ALDH1A1TSHRMAPK1CYP3A4
SCHEMBL68170 0.78
SCHEMBL3102919 0.76 CYP2A6 (0.32)
SCHEMBL3107531 0.74 KCNN4 (0.38) CYP19A1MEN1KMT2A
SCHEMBL3094555 0.74 TSHR (0.37) KIF11ALDH1A1TSHRMAPK1CYP3A4
SCHEMBL7024331 0.73 CYP19A1 (0.46) KIF11CYP19A1ALDH1A1TSHRMAPK1
SCHEMBL2223264 0.73 TSHR (0.30) TSHRMAPK1
Zinc Chloride SCHEMBL28148263 0.72 ALDH1A1 (0.42) ALDH1A1TSHRMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2163553-B1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO LTD (CN) 2013-12-25 EP disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS KIF11 1518/4885CYP19A1 1036/4885ALDH1A1 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.